Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The clinical spectrum of HbSC sickle cell disease-not a benign condition.
Nelson M, Noisette L, Pugh N, Gordeuk V, Hsu LL, Wun T, Shah N, Glassberg J, Kutlar A, Hankins JS, King AA, Brambilla D, Kanter J. Nelson M, et al. Among authors: kutlar a. Br J Haematol. 2024 Aug;205(2):653-663. doi: 10.1111/bjh.19523. Epub 2024 Jun 19. Br J Haematol. 2024. PMID: 38898714
Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.
Hankins JS, Potter MB, Fernandez ME, Melvin C, DiMartino L, Jacobs SR, Bosworth HB, King AA, Simon J, Glassberg JA, Kutlar A, Gordeuk VR, Shah N, Baumann AA, Klesges LM; Sickle Cell Disease Implementation Consortium. Hankins JS, et al. Among authors: kutlar a. Front Health Serv. 2023 Jan 20;2:1024541. doi: 10.3389/frhs.2022.1024541. eCollection 2022. Front Health Serv. 2023. PMID: 36925803 Free PMC article.
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.
Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, Hilliard L, Kutlar A, McClain KL, Olivieri NF, Porter JB, Vichinsky EP; Multi-Center Iron Overload Research Group. Fung EB, et al. Among authors: kutlar a. Transfusion. 2008 Sep;48(9):1971-80. doi: 10.1111/j.1537-2995.2008.01775.x. Epub 2008 May 29. Transfusion. 2008. PMID: 18513257 Free PMC article.
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study.
Kanter J, Mennito S, Nair SM, Manwani D, Kutlar A, Shah N, Keefe D, Madhamshetty H, Nassin M, Reshetnyak E, Mendonza AE, Liles D. Kanter J, et al. Among authors: kutlar a. Ther Adv Hematol. 2024 Nov 3;15:20406207241292508. doi: 10.1177/20406207241292508. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39497751 Free PMC article.
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
Kanter J, Ataga KI, Bhasin N, Guarino S, Kutlar A, Lanzkron S, Manwani D, McGann P, Stowell SR, Tubman VN, Yermilov I, Campos C, Broder MS. Kanter J, et al. Among authors: kutlar a. Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20. Ann Hematol. 2024. PMID: 38642304 Review.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM. Peffault de Latour R, et al. Among authors: kutlar a. N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695. N Engl J Med. 2024. PMID: 38477987
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
Hankins JS, Brambilla D, Potter MB, Kutlar A, Gibson R, King AA, Baumann AA, Melvin C, Gordeuk VR, Hsu LL, Nwosu C, Porter JS, Alberts NM, Badawy SM, Simon J, Glassberg JA, Lottenberg R, DiMartino L, Jacobs S, Fernandez ME, Bosworth HB, Klesges LM, Shah N. Hankins JS, et al. Among authors: kutlar a. Blood Adv. 2023 Dec 12;7(23):7190-7201. doi: 10.1182/bloodadvances.2023010670. Blood Adv. 2023. PMID: 37738155 Free PMC article. Clinical Trial.
269 results